Investment Analysts’ Weekly Ratings Updates for Emergent Biosolutions (EBS)

A number of research firms have changed their ratings and price targets for Emergent Biosolutions (NYSE: EBS):

• 12/16/2025 – Emergent Biosolutions had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 12/15/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/30/2025 – Emergent Biosolutions was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/25/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/22/2025 – Emergent Biosolutions was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/19/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Emergent Biosolutions had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/9/2025 – Emergent Biosolutions was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Emergent Biosolutions was upgraded by analysts at Weiss Ratings from a “sell (d)” rating to a “hold (c-)” rating.
• 11/1/2025 – Emergent Biosolutions was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/24/2025 – Emergent Biosolutions was upgraded by analysts at Zacks Research to a “hold” rating.

Insider Transactions at Emergent Biosolutions

In related news, EVP Coleen Glessner sold 30,608 shares of the firm’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president directly owned 144,319 shares of the company’s stock, valued at approximately $1,443,190. This trade represents a 17.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the sale, the director directly owned 98,417 shares of the company’s stock, valued at $1,178,051.49. The trade was a 18.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.20% of the company’s stock.

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.